Trials / Terminated
TerminatedNCT02205333
A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination With Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects With Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- MedImmune LLC · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to determine the best dose of MEDI6469 that is safe and tolerable when given as monotherapy and in combination with tremelimumab, MEDI4736 (durvalumab), or rituximab in participants with either advanced solid tumors or diffuse large B-cell lymphoma (DLBCL). Tremelimumab and MEDI4736 (durvalumab) will be tested with MEDI6469 in a set of participants with advanced solid tumors while rituximab will be tested with MEDI6469 in participants with DLBCL. MEDI6469 will be tested as monotherapy in participants with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MEDI6469 Monotherapy | single intravenous (IV) administration of MEDI6469 |
| BIOLOGICAL | MEDI6469 Plus Tremelimumab | MEDI6469 in combination with Tremelimumab |
| BIOLOGICAL | MEDI6469 Plus Durvalumab | MEDI6469 in combination with Durvalumab |
| BIOLOGICAL | MEDI6469 plus Rituximab | MEDI6469 in combination with Rituximab |
Timeline
- Start date
- 2014-08-13
- Primary completion
- 2016-04-08
- Completion
- 2016-04-08
- First posted
- 2014-07-31
- Last updated
- 2017-06-28
- Results posted
- 2017-05-08
Locations
13 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02205333. Inclusion in this directory is not an endorsement.